Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312
Retrieved on:
Wednesday, January 12, 2022
MSA, Patient, Technology, Immunotherapy, Vaccine, University, Private Securities Litigation Reform Act, Mayo Clinic, EMA, Antibody, COVID-19, Migraine, Safety, University of Texas at Austin, DLB, Risk, Social media, Synucleinopathy, GLOBE, Neurodegeneration, The Michael J. Fox Foundation, Health, U.S. Securities and Exchange Commission, Time, Nasdaq, BBB, Company, Efficiency, Multiple system atrophy, Therapy, Conditional sentence, Hypercholesterolemia, Neuron, Alpha-synuclein, Protein misfolding cyclic amplification, Brain, Lewy body, Security (finance), Dementia, Pharmaceutical industry, CSF, Part, PD
We are delighted to achieve another milestone for Vaxxinity as we initiate the next part of our clinical program in Parkinsons, an indication with clear unmet needs for a large patient population, said Mei Mei Hu, Chief Executive Officer of Vaxxinity.
Key Points:
- We are delighted to achieve another milestone for Vaxxinity as we initiate the next part of our clinical program in Parkinsons, an indication with clear unmet needs for a large patient population, said Mei Mei Hu, Chief Executive Officer of Vaxxinity.
- Developing vaccines that target chronic and difficult-to-treat diseases like Parkinsons are integral to our vision of providing cheaper, safer and more effective medicines to the world.
- Parkinsons disease currently affects approximately one million people in the United States and more than 10 million people worldwide.
- Clinical data from Part A of the Phase 1 trial indicate that UB-312 elicits antibody levels sufficient to cross the BBB (i.e., detectable in CSF).